华东医药：子公司与畅溪制药就改良型呼吸系统药物CXG87达成商业化合作

Core Viewpoint - Huadong Medicine has entered into an exclusive commercialization agreement with Hangzhou Changxi Pharmaceutical for the product CXG87, a modified budesonide/formoterol inhalation powder, aimed at treating asthma and other respiratory diseases [1] Group 1: Company Information - Huadong Medicine's wholly-owned subsidiary, Huadong Medicine (Hangzhou) Co., Ltd., is responsible for the commercialization of CXG87 in mainland China [1] - CXG87 is classified as a Category 2 new drug developed independently by Changxi Pharmaceutical [1] Group 2: Product Development - The clinical trial for CXG87 targeting asthma indications has completed the enrollment of all participants in its Phase III study [1] - The new drug application is expected to be submitted in the first half of 2026 [1]